Zacks Research Estimates AEON Biopharma Q3 Earnings

AEON Biopharma, Inc. (NASDAQ:AEON) – Zacks Research issued their Q3 2026 earnings estimates for AEON Biopharma in a note issued to investors on Monday, October 5th. Zacks Research analyst J. Vandermosten forecasts that the company will earn ($0.13) per share for the quarter. The consensus estimate for AEON Biopharma’s current full-year earnings is ($0.77) per share. Zacks Research also issued estimates for AEON Biopharma’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.22) EPS and FY2028 earnings at ($0.11) EPS.

Several other brokerages have also commented on AEON. Laidlaw initiated coverage on AEON Biopharma in a research note on Wednesday, September 9th. They set a “buy” rating and a $1.80 price target on the stock. Lake Street Capital reaffirmed a “buy” rating and issued a $2.00 price objective (up from $1.00) on shares of AEON Biopharma in a research report on Thursday, October 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $1.20 price objective (down from $5.00) on shares of AEON Biopharma in a research report on Friday, August 14th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1.67.

AEON Biopharma Price Performance

AEON Biopharma stock opened at $0.31 on Thursday. The stock has a market cap of $15.53 million, a price-to-earnings ratio of 1.73 and a beta of 0.69. The firm has a 50-day moving average of $0.27 and a two-hundred day moving average of $0.58. AEON Biopharma has a 1 year low of $0.18 and a 1 year high of $1.45.

Insider Transactions at AEON Biopharma

In other AEON Biopharma news, major shareholder Timothy P. Lynch acquired 1,150,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was acquired at an average cost of $0.21 per share, for a total transaction of $241,500.00. Following the purchase, the insider owned 6,500,000 shares in the company, valued at approximately $1,365,000. The trade was a 21.50% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 9.40% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic applications of botulinum toxin. Unlike companies that primarily target aesthetic uses, AEON is developing treatments for neurological and other medical conditions in which botulinum toxin may provide therapeutic benefits.

The company’s lead product candidate is ABP-450, an investigational botulinum neurotoxin type A complex licensed from Daewoong Pharmaceutical. AEON has evaluated ABP-450 in clinical programs targeting conditions including chronic migraine and cervical dystonia, and its broader development strategy may encompass additional therapeutic indications.